---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013495"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:36:42.000334+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma closes $4.7M registered direct offering with warrant coverage

## Summary
- Gross proceeds of ~$4.75M from sale of 2,764,710 shares at $1.70 each.
- Warrants issued to purchase 5,529,420 shares at $1.50, potential additional $8.3M.
- Net proceeds for working capital and antiviral drug development.
- H.C. Wainwright acted as placement agent; warrants expire 24 months after resale registration effective.

## SEC filing metadata
- accession: 0001493152-25-013495
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013495
- JSON: https://secwatch.observer/filing/0001493152-25-013495.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013495.txt

## Key facts
- Equity Issuances
  Cocrystal Pharma, Inc. issued 2,764,710 shares of common stock to accredited investors for at a price of $1.70 per share.
  - Security: common stock
  - Shares: 2,764,710 shares
  - Purchaser: accredited investors
  - Consideration: at a price of $1.70 per share
  source text: in a registered direct offering, an aggregate of 2,764,710 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $1.70 per share (the “Registered Direct Offering”) and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm
- Equity Issuances
  Cocrystal Pharma, Inc. issued warrants to purchase up to an aggregate of 5,529,420 shares of warrant to accredited investors for initial exercise price of $1.50 per share.
  - Security: warrant
  - Shares: warrants to purchase up to an aggregate of 5,529,420 shares
  - Purchaser: accredited investors
  - Consideration: initial exercise price of $1.50 per share
  source text: and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor Warrants”), at an initial exercise price of $1.50 per share (the “Private Placement” and together with the Registered Direct Offering, the “Offering”). The Shares were offered at-the-market under rules of The Nasdaq Stock Market,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm
- Equity Issuances
  Cocrystal Pharma, Inc. issued warrants to acquire up to an aggregate of 207,353 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses.
  - Security: warrant
  - Shares: warrants to acquire up to an aggregate of 207,353 shares of Common Stock
  - Purchaser: H.C. Wainwright & Co., LLC
  - Consideration: cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses
  source text: medicines for use in the treatment of human viral diseases. 2 Under the SPA, no later than October 10, 2025, the Company is required to file a registration statement on Form S-1 registering the resale of the shares of Common Stock issued or issuable upon exercise of the Investor Warrants (the “Resale Registration Statement”). The Company is required to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315225013495/0001493152-25-013495-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.